HEMGENIX Drug Profile

Summary for Tradename: HEMGENIX

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HEMGENIX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HEMGENIX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for HEMGENIX Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Hemgenix

Last updated: February 21, 2026

Does Hemgenix have a competitive market position?

Hemgenix, developed by CSL Behring, is an engineered gene therapy targeting hemophilia B. It is the first approved gene therapy for this indication in the U.S., gaining FDA approval in November 2022. The therapy is designed for adult patients with severe hemophilia B, providing a one-time infusion aimed at reducing bleeding incidents and dependence on factor IX replacement therapy.

Market size:

• Hemophilia B affects approximately 1 in 30,000 male births globally.
• The global hemophilia market was valued at $10.4 billion in 2021, with hemophilia B representing roughly 25% ($2.6 billion) of that figure.
• Premised on underdiagnosis and access disparities, the addressable market for Hemgenix will expand with increased adoption and diagnosis rates.

Market penetration factors:

• Limited competition: Hemgenix is the first approved gene therapy for hemophilia B.
• Efficacy: Demonstrates a significant rise in factor IX levels, reducing bleeding episodes.
• Safety: Reported adverse events include transaminitis and infusion reactions, manageable within clinical settings.
• Pricing: Priced at approximately $3.5 million per treatment in the U.S., positioning it in the high-end biologic segment.

How does Hemgenix’s pricing influence its financial trajectory?

The $3.5 million price tag positions Hemgenix among the highest-priced gene therapies globally. This premium reflects the treatment’s potential to eliminate lifelong factor IX replacement therapy for eligible patients.

Reimbursement landscape:

• Payers are adopting value-based approaches.
• Negotiations may focus on outcome-based reimbursement models, where coverage hinges on long-term efficacy and safety data.
• Initial uptake hinges on formulary approvals, with early access routes via specialty pharmacy programs.

Revenue projection considerations:

• Estimations assume initial uptake of 10% of the eligible population in the U.S. within 5 years.
• With approximately 3,000 severe hemophilia B patients in the U.S., initial market share may target 300 patients.
• At full adoption, annual revenue could reach $1 billion, considering evolving treatment paradigms and global expansion.

What factors influence Hemgenix’s sales growth?

Regulatory and Reimbursement Trends

• Expansion into Europe and Asia will depend on local regulatory approval timelines and reimbursement negotiations.
• European agencies, including EMA, granted Priority Medicines (PRIME) designation, potentially accelerating approval processes.

Clinical Efficacy and Safety Data

• Longer-term clinical trial data confirming durability of factor IX activity will influence clinician prescribing behavior.
• Post-marketing surveillance for adverse events will shape payer confidence.

Market Adoption & Physician Acceptance

• Education initiatives are necessary to familiarize physicians with gene therapy technology.
• Patient acceptance depends on perceived safety and long-term benefits.

Competitive Landscape

• Other gene therapies in development, such as UniQure’s AMT-061 (Etranacogene dezaparvovec), are awaiting approval, potentially competing with Hemgenix upon market entry.
• The absence of immediate competitors gives Hemgenix a temporary monopoly but leaves room for future entrants.

What is the financial outlook based on current trends?

Short-term outlook (next 1-2 years):

• Limited initial sales driven by early access programs and institutional adoption.
• Revenue estimates ranging from $50 million to $150 million by year-end 2023, depending on distribution speed and reimbursement.

Medium-term outlook (3-5 years):

• Accelerated growth with broader insurance approval and increased clinician familiarity.
• Potential to reach annual revenues of $500 million, contingent on global approval and increased patient awareness.

Long-term outlook (5+ years):

• Sustained revenue growth possible if the therapy demonstrates durable efficacy over decades.
• Market share could expand beyond severe cases to include moderate patients if applicable safety data emerge.

Key market risks and challenges

• High upfront treatment cost may slow initial uptake.
• Long-term safety data are pending, and unforeseen adverse effects could limit adoption.
• Reimbursement hurdles may delay access in certain markets.
• Competitors could introduce alternative gene therapies or improved vector designs.

Key takeaways

• Hemgenix is a first-in-class gene therapy for hemophilia B with a favorable market position owing to the lack of direct competition.
• Its high cost necessitates outcome-based reimbursement models and may limit short-term adoption.
• Market penetration depends on regulatory approvals outside the U.S., payer negotiations, and physician acceptance.
• Revenue projections assume gradual uptake, with potential to reach billion-dollar annual sales within 5 years.
• Future growth hinges on long-term safety data, international approval timelines, and advances by competitors.

FAQs

1. What is the current regulatory status of Hemgenix?
   Hemgenix received FDA approval in November 2022. It is under review or seeking approval in Europe and other regions.

2. How does Hemgenix compare with traditional hemophilia B treatments?
   Hemgenix offers a one-time infusion, reducing or eliminating the need for lifelong factor IX replacement therapy, which is costly and burdensome.

3. What are main concerns regarding Hemgenix’s safety?
   Potential adverse events include liver transaminase elevations and infusion reactions; long-term safety data are still being collected.

4. What are the implications of premium pricing for Hemgenix?
   The high price reflects the therapy’s potentially curative nature but may limit access and impact payer negotiations negatively.

5. How does the competition landscape look for Hemgenix?
   Other gene therapies are in pipeline stages, but none have yet received approval. Hemgenix currently holds a market advantage.

---

References

[1] CSL Behring. (2022). Hemgenix (etranacogene dezaparvovec) prescribing information.
[2] Global Hemophilia Market Report. (2022). Market Research Future.
[3] U.S. Food and Drug Administration. (2022). Hemgenix FDA approval announcement.
[4] European Medicines Agency. (2022). Priority Medicines (PRIME) for hemophilia gene therapies.